si-544

DRUG2 trials

Sponsors

selectION Therapeutics GmbH

Conditions

Atopic DermatitisPsoriasis VulgarisPsoriatic Arthritis

Phase 1

A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis

CompletedNCT05383378

selectION Therapeutics GmbHAtopic Dermatitis

Start: 2022-08-30End: 2023-11-01Updated: 2023-11-13

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

CompletedNCT06191042

selectION Therapeutics GmbHPsoriasis Vulgaris, Psoriatic Arthritis

Start: 2024-01-22End: 2025-06-23Updated: 2025-07-03